|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.44 USD | +0.46% |
|
+2.92% | +3.67% |
| 14/01 | Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating | MT |
| 13/01 | Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.5 | 7.54 | 4.43 | 3.55 | 14.64 | |||||
Return on Total Capital | 3.84 | 8.54 | 5.07 | 4.13 | 17.46 | |||||
Return On Equity % | 6.27 | 11.3 | 7.76 | 8.74 | 23.13 | |||||
Return on Common Equity | 6.27 | 11.3 | 7.76 | 8.74 | 23.13 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 96.6 | 96.32 | 96.41 | 96.04 | 96.49 | |||||
SG&A Margin | 29.71 | 27.99 | 28.54 | 29.65 | 22.69 | |||||
EBITDA Margin % | 12.34 | 20.93 | 13.8 | 10.74 | 33.14 | |||||
EBITA Margin % | 11.42 | 19.98 | 12.51 | 9.34 | 31.81 | |||||
EBIT Margin % | 11.42 | 19.98 | 12.51 | 9.34 | 31.81 | |||||
Income From Continuing Operations Margin % | 11.32 | 16.1 | 11.31 | 11.35 | 24.04 | |||||
Net Income Margin % | 11.32 | 16.1 | 11.31 | 11.35 | 24.04 | |||||
Net Avail. For Common Margin % | 11.32 | 16.1 | 11.31 | 11.35 | 24.04 | |||||
Normalized Net Income Margin | 8.45 | 12.81 | 9.09 | 8.79 | 22.1 | |||||
Levered Free Cash Flow Margin | 13.78 | 17.45 | 9.16 | 6.85 | 21.41 | |||||
Unlevered Free Cash Flow Margin | 13.78 | 17.45 | 9.16 | 6.85 | 21.41 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.49 | 0.6 | 0.57 | 0.61 | 0.74 | |||||
Fixed Assets Turnover | 9.82 | 11.06 | 6.51 | 5.17 | 6.63 | |||||
Receivables Turnover (Average Receivables) | 7.03 | 6.47 | 6.48 | 8.09 | 8.63 | |||||
Inventory Turnover (Average Inventory) | 1.98 | 2.18 | 1.91 | 2.87 | 3.84 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.06 | 5.43 | 4.99 | 3.34 | 3.63 | |||||
Quick Ratio | 6.7 | 5.19 | 4.72 | 3.16 | 3.45 | |||||
Operating Cash Flow to Current Liabilities | 1.02 | 1.19 | 1.12 | 0.85 | 1.73 | |||||
Days Sales Outstanding (Average Receivables) | 52.07 | 56.41 | 56.35 | 45.09 | 42.43 | |||||
Days Outstanding Inventory (Average Inventory) | 184.56 | 167.29 | 191.59 | 127.35 | 95.35 | |||||
Average Days Payable Outstanding | 154.68 | 147.15 | 163.05 | 214.32 | 162.01 | |||||
Cash Conversion Cycle (Average Days) | 81.95 | 76.54 | 84.88 | -41.89 | -24.23 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 2.77 | 2.55 | 8.35 | 9.53 | 9.62 | |||||
Total Debt / Total Capital | 2.7 | 2.49 | 7.71 | 8.7 | 8.77 | |||||
LT Debt/Equity | 2.61 | 2.32 | 7.64 | 8.39 | 8.5 | |||||
Long-Term Debt / Total Capital | 2.54 | 2.26 | 7.05 | 7.66 | 7.76 | |||||
Total Liabilities / Total Assets | 12.08 | 15.5 | 18.98 | 23.06 | 23.87 | |||||
EBIT / Interest Expense | - | - | - | - | - | |||||
EBITDA / Interest Expense | - | - | - | - | - | |||||
(EBITDA - Capex) / Interest Expense | - | - | - | - | - | |||||
Total Debt / EBITDA | 0.4 | 0.18 | 0.85 | 0.93 | 0.29 | |||||
Net Debt / EBITDA | -8.91 | -4.58 | -4.52 | -3.35 | -2.03 | |||||
Total Debt / (EBITDA - Capex) | 0.53 | 0.23 | 0.96 | 1.12 | 0.3 | |||||
Net Debt / (EBITDA - Capex) | -11.64 | -5.78 | -5.09 | -4.06 | -2.11 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 2.04 | 45.31 | 12.27 | 13.6 | 18.49 | |||||
Gross Profit, 1 Yr. Growth % | 1.92 | 45.29 | 12.38 | 13.17 | 19.05 | |||||
EBITDA, 1 Yr. Growth % | -67.85 | 151.92 | -25.95 | -11.58 | 265.59 | |||||
EBITA, 1 Yr. Growth % | -69.59 | 160.46 | -29.71 | -15.19 | 303.75 | |||||
EBIT, 1 Yr. Growth % | -69.59 | 160.46 | -29.71 | -15.19 | 303.75 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -65.18 | 106.71 | -21.11 | 13.98 | 150.89 | |||||
Net Income, 1 Yr. Growth % | -65.18 | 106.71 | -21.11 | 13.98 | 150.89 | |||||
Normalized Net Income, 1 Yr. Growth % | -66.57 | 124.82 | -20.33 | 9.89 | 197.83 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -65.69 | 105.71 | -22.22 | 16.07 | 170.77 | |||||
Accounts Receivable, 1 Yr. Growth % | 33.91 | 75.7 | -24.01 | 10.53 | 11.81 | |||||
Inventory, 1 Yr. Growth % | 62.76 | 31.09 | 21.12 | -47.98 | 29.24 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 21.68 | 35.11 | 131.6 | 4.79 | -19.34 | |||||
Total Assets, 1 Yr. Growth % | 13.35 | 22.41 | 17.4 | -4.2 | 0.18 | |||||
Tangible Book Value, 1 Yr. Growth % | 11.91 | 18.26 | 12.94 | -9.26 | -0.9 | |||||
Common Equity, 1 Yr. Growth % | 11.46 | 17.64 | 12.57 | -9.02 | -0.87 | |||||
Cash From Operations, 1 Yr. Growth % | -60.34 | 91.79 | -9.53 | -8.08 | 110 | |||||
Capital Expenditures, 1 Yr. Growth % | 136.44 | 111.65 | -48.91 | 46.07 | -29.74 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -63.28 | 86.37 | -41.08 | -15.01 | 270.2 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -63.28 | 86.37 | -41.08 | -15.01 | 270.2 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7.55 | 21.77 | 27.73 | 12.94 | 16.02 | |||||
Gross Profit, 2 Yr. CAGR % | 7.3 | 21.6 | 27.78 | 12.77 | 16.07 | |||||
EBITDA, 2 Yr. CAGR % | -47.65 | -10.85 | 36.58 | -19.09 | 79.79 | |||||
EBITA, 2 Yr. CAGR % | -49.37 | -11.92 | 35.3 | -22.79 | 85.05 | |||||
EBIT, 2 Yr. CAGR % | -49.37 | -11.92 | 35.3 | -22.79 | 85.05 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -59.75 | -15.16 | 27.7 | -5.18 | 69.11 | |||||
Net Income, 2 Yr. CAGR % | -59.75 | -15.16 | 27.7 | -5.18 | 69.11 | |||||
Normalized Net Income, 2 Yr. CAGR % | -45.72 | -14.04 | 33.83 | -6.43 | 80.91 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -60.2 | -15.98 | 26.49 | -4.99 | 77.28 | |||||
Accounts Receivable, 2 Yr. CAGR % | -0.58 | 53.39 | 15.55 | -8.35 | 11.17 | |||||
Inventory, 2 Yr. CAGR % | 46.01 | 46.07 | 26 | -20.62 | -18 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 39.46 | 28.22 | 76.89 | 55.78 | -8.07 | |||||
Total Assets, 2 Yr. CAGR % | 22.59 | 17.79 | 19.88 | 6.05 | -2.04 | |||||
Tangible Book Value, 2 Yr. CAGR % | 21.8 | 15.04 | 15.57 | 1.23 | -5.17 | |||||
Common Equity, 2 Yr. CAGR % | 20.81 | 14.51 | 15.08 | 1.2 | -5.03 | |||||
Cash From Operations, 2 Yr. CAGR % | -29.1 | -12.79 | 31.72 | -8.81 | 38.94 | |||||
Capital Expenditures, 2 Yr. CAGR % | -4.54 | 123.7 | -4.45 | -13.61 | 1.31 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -11.74 | -17.7 | 4.79 | -29.23 | 77.38 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -11.74 | -17.7 | 4.79 | -29.23 | 77.38 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 29.71 | 18.89 | 18.52 | 22.83 | 14.76 | |||||
Gross Profit, 3 Yr. CAGR % | 29.56 | 18.6 | 18.45 | 22.71 | 14.83 | |||||
EBITDA, 3 Yr. CAGR % | -10.19 | -12.28 | -16.2 | 18.15 | 33.77 | |||||
EBITA, 3 Yr. CAGR % | -12.29 | -13.31 | -18.3 | 15.8 | 34.01 | |||||
EBIT, 3 Yr. CAGR % | -12.29 | -13.31 | -18.3 | 15.8 | 34.01 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -10.17 | -30.56 | -17.19 | 22.95 | 31.15 | |||||
Net Income, 3 Yr. CAGR % | -10.17 | -30.56 | -17.19 | 22.95 | 31.15 | |||||
Normalized Net Income, 3 Yr. CAGR % | -5.8 | -13.42 | -16.19 | 25.32 | 37.64 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -10.8 | -31.19 | -18.12 | 22.92 | 34.71 | |||||
Accounts Receivable, 3 Yr. CAGR % | 27.67 | 20.2 | 21.37 | 13.85 | -2.07 | |||||
Inventory, 3 Yr. CAGR % | 46.6 | 40.85 | 37.23 | -6.17 | -6.62 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 62.47 | 37.99 | 56.15 | 48.56 | 25.09 | |||||
Total Assets, 3 Yr. CAGR % | 48.3 | 22.53 | 17.66 | 11.24 | 4.06 | |||||
Tangible Book Value, 3 Yr. CAGR % | 101.69 | 20.61 | 14.34 | 6.62 | 0.52 | |||||
Common Equity, 3 Yr. CAGR % | 87.52 | 19.75 | 13.86 | 6.41 | 0.5 | |||||
Cash From Operations, 3 Yr. CAGR % | 8.06 | -1.21 | -11.71 | 16.84 | 20.42 | |||||
Capital Expenditures, 3 Yr. CAGR % | 12.8 | 24.48 | 29.24 | 10.07 | -19.36 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 13.8 | 12.76 | -26.37 | -2.27 | 22.85 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 11.66 | 12.76 | -26.37 | -2.27 | 22.85 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 92.69 | 49.61 | 28.91 | 16.47 | 17.51 | |||||
Gross Profit, 5 Yr. CAGR % | 94.27 | 49.45 | 28.77 | 16.23 | 17.49 | |||||
EBITDA, 5 Yr. CAGR % | 0.69 | 63.49 | 5.73 | -15.07 | 13.73 | |||||
EBITA, 5 Yr. CAGR % | -1.1 | 60.75 | 3.81 | -17.23 | 13.3 | |||||
EBIT, 5 Yr. CAGR % | -1.1 | 60.75 | 3.81 | -17.23 | 13.3 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -7.12 | 26.9 | 3.4 | -21.34 | 10.18 | |||||
Net Income, 5 Yr. CAGR % | -7.12 | 26.9 | 3.4 | -21.34 | 10.18 | |||||
Normalized Net Income, 5 Yr. CAGR % | -3.5 | 38.65 | 7.96 | -10.69 | 14.01 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -14.66 | 20.77 | 2.57 | -21.71 | 11.53 | |||||
Accounts Receivable, 5 Yr. CAGR % | 98.78 | 47.53 | 22.68 | 7.84 | 17.18 | |||||
Inventory, 5 Yr. CAGR % | 51.64 | 52.46 | 37.98 | 11.98 | 11.68 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 138.39 | 135.23 | 68.09 | 44.85 | 26.33 | |||||
Total Assets, 5 Yr. CAGR % | 45.1 | 34.44 | 36.2 | 15.65 | 9.35 | |||||
Tangible Book Value, 5 Yr. CAGR % | 54.76 | 142.44 | 61.42 | 12.45 | 6.09 | |||||
Common Equity, 5 Yr. CAGR % | 67.91 | 89.98 | 54.25 | 11.95 | 5.89 | |||||
Cash From Operations, 5 Yr. CAGR % | 8.18 | 13.76 | 16.97 | -4.32 | 5.84 | |||||
Capital Expenditures, 5 Yr. CAGR % | 132.46 | 106.68 | 5.56 | 3.98 | 17.25 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 14.56 | 73.65 | 9.84 | -6.41 | 4.66 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 17.58 | 133.25 | 8.59 | -6.41 | 4.66 |
- Stock Market
- Equities
- EXEL Stock
- Financials Exelixis, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















